Peptides for Longevity: Research for Over-65s

Ageing is not a single process but a convergence of interconnected biological changes:

• •Immunosenescence: The immune system declines with age, increasing infection susceptibility and reducing vaccine responses
• •Somatopause: Growth hormone secretion drops ~14% per decade after age 30
• •Mitochondrial dysfunction: Cellular energy production becomes less efficient
• •Telomere shortening: Protective chromosome caps erode with each cell division
• •Chronic low-grade inflammation (inflammaging): Persistent low-level inflammation accelerates tissue damage
• •Sarcopenia: Progressive loss of skeletal muscle mass and strength

Peptide research for longevity targets these specific mechanisms. While no peptide has been proven to extend human lifespan, several compounds are being investigated for their effects on the hallmarks of ageing.

Epitalon (Epithalon) A synthetic tetrapeptide studied for its effects on telomerase — the enzyme that maintains telomere length. Russian research (Professor Vladimir Khavinson) suggests epitalon may activate telomerase in human somatic cells and was associated with reduced mortality in elderly populations in limited clinical studies. However, the evidence base is narrow and largely from a single research group.

MOTS-c (Mitochondrial ORF of the Twelve S rRNA-c) A mitochondrial-derived peptide that acts as a metabolic regulator. Research shows MOTS-c improves insulin sensitivity, enhances exercise capacity, and may protect against age-related metabolic decline. Animal studies demonstrate improved physical performance in aged mice. Human trials are very limited.

Humanin Another mitochondrial-derived peptide with neuroprotective and cytoprotective properties. Humanin levels decline with age, and lower levels correlate with Alzheimer's disease markers. Research suggests it may protect against oxidative stress and apoptosis.

SS-31 (Elamipretide) Targets the inner mitochondrial membrane, stabilising cardiolipin and improving electron transport chain efficiency. Clinical trials exist for mitochondrial myopathies and heart failure. Potentially relevant to age-related mitochondrial decline.

Thymosin Alpha-1 An immune-modulating peptide that enhances T-cell function and NK cell activity. Approved in some countries for hepatitis B and as an immune adjuvant. Particularly relevant for immunosenescence in the elderly — potentially improving vaccine responses and infection resistance.

GHK-Cu A naturally occurring copper peptide that declines significantly with age (60% reduction by age 60). Research shows effects on collagen synthesis, wound healing, antioxidant gene expression, and anti-inflammatory signalling. Available both as a topical skincare product and a research injectable.

Older adults face unique safety considerations with peptide use:

Physiological differences: - Reduced renal function: Age-related kidney decline affects peptide clearance — lower doses may be needed - Polypharmacy: Over-65s take an average of 4+ medications, increasing interaction risk - Altered body composition: Less muscle mass and more fat tissue affect distribution - Reduced hepatic function: Liver metabolism slows with age

Specific risks: - GH secretagogues: Elevated IGF-1 may theoretically promote growth of existing malignancies — cancer screening is essential before considering GH-stimulating peptides - Insulin resistance: GH elevation can worsen glucose control — particularly relevant for the ~30% of UK over-65s with diabetes or prediabetes - Cardiovascular effects: Any compound affecting blood pressure, heart rate, or fluid balance requires careful monitoring - Fall risk: Peptides causing dizziness, orthostatic hypotension, or fatigue could increase fall risk

Essential monitoring: - Regular blood work (metabolic panel, IGF-1, liver function, renal function) - Blood pressure monitoring - Cancer screening up-to-date - Medication interaction review with pharmacist - Bone density monitoring if relevant

While peptide research for longevity is intriguing, the strongest evidence for healthy ageing comes from established interventions:

Exercise (strongest evidence): - Resistance training 2-3x weekly combats sarcopenia - Aerobic exercise (150 min/week) reduces cardiovascular and dementia risk - Balance training reduces falls — the leading cause of injury-related death in over-65s - NHS Active at Every Age programmes are available locally

Nutrition: - Protein intake ≥1.0-1.2g/kg/day (higher than younger adults) - Mediterranean diet pattern associated with reduced all-cause mortality - Vitamin D supplementation (10mcg daily — NHS recommended for all UK adults in autumn/winter, year-round for over-65s) - Adequate calcium for bone health

Medical management: - Keep up with NHS Health Checks and cancer screening - Flu, COVID, pneumococcal, and shingles vaccinations (all NHS-funded for over-65s) - Blood pressure and cholesterol management - Cognitive engagement and social connection

Peptides, if considered at all, should complement — not replace — these foundational strategies.

*This guide is for educational purposes only. Over-65s should discuss any supplement or peptide with their GP, particularly given polypharmacy and age-related physiological changes.*